Across TCGA pan-cancer cohorts, LRRC9 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LRRC9 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LRRC9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRRC9 expression acts as an unfavorable survival marker.
UCEC are the cancer types where LRRC9 Mutation most reproducibly stratifies survival.